{"links":{"feed":"https://www.erudio.com/reports/litespark-001-nct02974738/feed.json","html":"https://www.erudio.com/reports/litespark-001-nct02974738","json":"https://www.erudio.com/reports/litespark-001-nct02974738.json","markdown":"https://www.erudio.com/reports/litespark-001-nct02974738.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"litespark-001-nct02974738"}},"request":"https://www.erudio.com/contact?report=litespark-001-nct02974738"},"offer":{"cited_clinicians":10,"cited_commentary_sources":14,"verified_hcp_statements":87,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":14},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"litespark-001-nct02974738"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=litespark-001-nct02974738","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/litespark-001-nct02974738","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 87 verified statements · 45 from 10 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-21T10:22:32.548175Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: maximum tolerated dose (MTD)"},{"claim_count":7,"coverage":"discussed","id":"T2","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":6,"coverage":"discussed","id":"T3","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":17,"coverage":"discussed","id":"T4","registry_field":"outcomesModule","source_count":8,"title":"Safety and tolerability"},{"claim_count":6,"coverage":"discussed","id":"T5","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":21,"coverage":"discussed","id":"A1","source_count":11,"title":"Activity, durability and the importance of prior treatment burden"},{"claim_count":13,"coverage":"discussed","id":"A2","source_count":5,"title":"Target rationale, scientific novelty and unresolved response or resistance"},{"claim_count":10,"coverage":"discussed","id":"A3","source_count":4,"title":"The subsequent phase III comparator debate"},{"claim_count":13,"coverage":"discussed","id":"A4","source_count":6,"title":"Post-IO positioning, combination development and research engagement"},{"claim_count":3,"coverage":"discussed","id":"A5","source_count":1,"title":"LITESPARK-013 as later dose-evaluation context"},{"claim_count":2,"coverage":"discussed","id":"A6","source_count":1,"title":"Use of the early cohort as a benchmark and questions after belzutifan exposure"}],"counts":{"beyond_population_findings":2,"beyond_population_statements":12,"cited_clinicians":10,"cited_clinicians_by_role":{"physician":2,"physician, Hematology and oncology":1,"physician, Medical oncology":6,"physician, Urology":1},"cited_physicians":10,"cited_sources":16,"claims_by_expression_type":{"comparison":5,"experience":3,"interpretation":30,"opinion":18,"primary_context":5,"question":2,"restatement":16,"uncertainty":2,"unspecified":6},"claims_by_kind":{"objective_result":3,"protocol_statement":2,"publication_statement":10,"source_observation":72},"clinician_statements":45,"evidence_units":51,"findings":6,"organisational_accounts":1,"people_cited":14,"people_identity_verified":14,"people_total":14,"screened_sources":26,"verified_claims":87},"findings_index":[{"cited_clinicians":5,"id":"F1","structure":{"claims":27,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":8,"views":17},"limitations":3,"links":{"context":2,"support":31},"ma_question":true,"named_voices":6,"passages":21,"sources":13,"sources_by_kind":{"commentary":6,"media":5,"publication":2}},"title":"Late-line ccRCC: most speakers highlight responses; a clinician flags single-arm PFS","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-b6e443cb75219f54d5ae","claim-dab7f19be53a8913c542"],"clause":"a clinician flags single-arm PFS","holders":1},"cited_claim_ids":["claim-44024417c6523a808701","claim-9a1a82a8f14c6a1a980e","claim-d297cd647c1aac32ca7d","claim-b6e443cb75219f54d5ae","claim-487d6529bcc99cf62962","claim-34b39a4b773e31a4d76e","claim-3c0da2dd005c0afc501e","claim-b9894bbdc8ab1f51f22c","claim-c2eb83444c1cf087da1a","claim-d401e9407ad010ef307f","claim-afbd3d6ec4a2ca6df002","claim-dab7f19be53a8913c542","claim-2c59c17b6d35405c3f66","claim-df426e0df75fcb59cb0f"],"clinicians":false,"holders":4,"speakers":6,"view":"reading"},"evidence_line":"27 statements from 6 speakers in 13 sources, 5 of them podcasts or videos","holder_line":"4 of the 6 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician flags single-arm PFS”"},{"cited_clinicians":3,"id":"F2","structure":{"claims":27,"claims_by_group":{"comparisons":4,"experience":1,"questions":0,"restated":10,"views":12},"limitations":6,"links":{"context":1,"support":29},"ma_question":true,"named_voices":4,"passages":20,"sources":11,"sources_by_kind":{"commentary":3,"media":6,"publication":2}},"title":"Belzutifan safety: how speakers weigh anemia, hypoxia and manageability","title_holders":{"cited_claim_ids":["claim-44024417c6523a808701","claim-9a1a82a8f14c6a1a980e","claim-ae729f86671f93a92093","claim-7bc280ea9494a77b1cbf","claim-34b39a4b773e31a4d76e","claim-726fac8be906f4c32ea6","claim-4f5b45e174118ba6bc2e","claim-14acb5307053228de654","claim-13290158787a1d793989","claim-df3f6ee18c3db91878f4","claim-81cf9dbe31b1080565c4","claim-e668ee1b7c8b0177fa2c","claim-d401e9407ad010ef307f","claim-659638117e17436fc433","claim-5d79fe740b2b1447b53e"],"clinicians":false,"holders":4,"speakers":4,"view":"reading"},"evidence_line":"27 statements from 4 speakers in 11 sources, 6 of them podcasts or videos","holder_line":"4 of the 4 named speakers in this finding hold this view"},{"cited_clinicians":1,"id":"F4","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":4,"views":8},"limitations":3,"links":{"context":0,"support":15},"ma_question":true,"named_voices":1,"passages":8,"sources":6,"sources_by_kind":{"commentary":1,"media":4,"publication":1}},"title":"HIF-2 targeting: a clinician sees proof of principle but hopes for biomarker work","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-3b5655be89123def935e"],"clause":"hope for biomarker work","holders":1},"cited_claim_ids":["claim-afbd3d6ec4a2ca6df002","claim-afaa046ccc38fd9dc373","claim-d8eadd88769aed5253df"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"14 statements from 1 speaker in 6 sources, 4 of them podcasts or videos","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “hope for biomarker work”"},{"cited_clinicians":4,"id":"F5","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":1,"views":8},"limitations":3,"links":{"context":0,"support":14},"ma_question":true,"named_voices":7,"passages":12,"sources":4,"sources_by_kind":{"commentary":1,"media":2,"publication":1}},"title":"Everolimus control: most speakers question it; some see prior-therapy logic","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-b5664e61cd26d59d53d1","claim-6d934459efbeb8605a09","claim-35093d938ec9282b16a2"],"clause":"some see prior-therapy logic","holders":3},"cited_claim_ids":["claim-02b31d8ba5d0f87f89fc","claim-d77bfb2d20b575777ec3","claim-6f4abfd514b3d0c0e3d6","claim-b5664e61cd26d59d53d1","claim-35093d938ec9282b16a2"],"clinicians":false,"holders":5,"speakers":7,"view":"reading"},"evidence_line":"11 statements from 7 speakers in 4 sources, 2 of them podcasts or videos","holder_line":"5 of the 7 named speakers in this finding hold this view; 3 of the 7 hold its caveat, “some see prior-therapy logic”"},{"cited_clinicians":4,"id":"F6","population":"beyond","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":1,"views":11},"limitations":4,"links":{"context":0,"support":15},"ma_question":true,"named_voices":5,"passages":12,"sources":8,"sources_by_kind":{"commentary":2,"media":5,"publication":1}},"title":"Belzutifan: what speakers say","evidence_line":"14 statements from 5 speakers in 8 sources, 5 of them podcasts or videos"},{"cited_clinicians":0,"id":"F8","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":0},"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"XmAb819: what speakers say","evidence_line":"2 statements in 1 source"}],"open_question":{"basis":"From finding F1 (27 statements from 6 speakers in 13 sources)","cited_claim_ids":["claim-0b3569fab4111f1cf962","claim-b6e443cb75219f54d5ae","claim-34b39a4b773e31a4d76e","claim-68fb0119e9fa86006afa","claim-b9894bbdc8ab1f51f22c","claim-dab7f19be53a8913c542","claim-2c59c17b6d35405c3f66","claim-f1f95295144afc40e0ba","claim-b0ff4fe9653f24f571a6"],"finding_ids":["F1"],"question":"What do clinicians say remains uncertain when interpreting PFS with belzutifan in heavily pretreated advanced clear-cell RCC from the single-arm LITESPARK-001 study?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers welcome activity in heavily pretreated ccRCC; one stresses single-arm PFS caution"},{"id":"section-2","level":2,"title":"Speakers describe a different, manageable safety profile, with particular attention to anemia and hypoxia"},{"id":"section-3","level":2,"title":"One results presenter reads HIF-2 targeting as proof of principle and seeks biomarkers of response and resistance"},{"id":"section-4","level":2,"title":"X accounts disagree on the subsequent phase III comparator, depending on prior treatment"},{"id":"section-5","level":2,"title":"Beyond the trial population"},{"id":"section-6","level":3,"title":"Speakers support further sequencing and combination studies; one discussion questions cabozantinib-combination applicability"},{"id":"section-7","level":3,"title":"One unverified X account prefers a phase III benchmark and prioritizes post-belzutifan activity"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, single group, phase1","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":3}],"id":"T1","label":"Primary endpoint: maximum tolerated dose (MTD)"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":2}],"id":"T2","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":4},{"id":"F4","shared_claims":2}],"id":"T3","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":17},{"id":"F4","shared_claims":1}],"id":"T4","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T5","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-21T10:22:32.548175Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-21T10:48:05Z","record_hash":"a87067ea219cf8f4a127974fdfadb362826979283e64ce7b24670108b3cdaaa1","release_hash":"3ac35ab5d4e066e1e11e68f6838e01ebdf4184145ca831aea924c999bb0c5e32","report_id":"erudio-nct02974738","run_id":"9766289d-6c77-40d7-a5ff-e8c311ae5147","schema_version":"5.0","slug":"litespark-001-nct02974738","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"The clinicians cited read LITESPARK-001 as supporting further development because disease control persisted despite prior treatment. A medical oncologist described in the sources as presenting the results cautions against overinterpreting progression-free survival and hopes biomarker studies will explain variable responses. A urologist favors cabozantinib over everolimus for subsequent testing, whereas medical oncologists consider everolimus defensible after cabozantinib or axitinib. Comparative advantages in benefit or safety remain unproven.","examples":[],"meta_description":"26 sources screened · 87 verified statements (45 from clinicians verified by NPI or staff page) from 16 sources · 6 findings. Updated Nov 21, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-21T10:48:05Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":26},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","14 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 38 sources about other trials or topics are not included.","Most substantive views concern previously treated or refractory clear-cell RCC. They cannot establish how clinicians interpret the trial's other solid-tumor or glioblastoma populations.","Several accounts discuss the clinical setting and intervention without naming LITESPARK-001. Their views are preserved as attributed context rather than automatically treated as this trial's results.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Different dates, follow-up durations, adverse-event definitions and treatment-attribution categories limit direct comparison across reports. They do not by themselves establish a change in opinion or a contradiction.","Early phase I/II activity and observational toxicity comparisons do not establish randomized efficacy or safety advantages. Personal long-duration treatment examples are not cohort medians.","The subsequent phase III comparator debate, LITESPARK-013 dose comparison, combination studies and post-belzutifan sequencing arguments concern separate development questions and must not be assigned to LITESPARK-001's own arms or outcomes.","No standalone protocol or exact belzutifan product label was reviewed. Supportive-care descriptions are study-management accounts, not a complete prescribing or routine-care assessment.","Multiple posts, relays or publications may repeat the same underlying presentation or data and should not be counted as independent HCP agreement."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":2,"registry":0,"regulatory":0,"x_thread":8,"x_video":1,"youtube":5},"by_evidence_role":{"commentary":14,"results":2},"count":16,"evidence_window":{"end":"2026-10-20","start":"2018-06-01"},"retrieval_snapshot":"2026-11-21T09:43:09.124301Z","timeline":[{"count":1,"week":"2018-W22"},{"count":1,"week":"2019-W39"},{"count":2,"week":"2020-W07"},{"count":1,"week":"2020-W08"},{"count":1,"week":"2020-W11"},{"count":1,"week":"2021-W06"},{"count":1,"week":"2021-W09"},{"count":2,"week":"2021-W16"},{"count":1,"week":"2021-W31"},{"count":1,"week":"2022-W22"},{"count":1,"week":"2023-W45"},{"count":1,"week":"2026-W43"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT02974738:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02974738:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:33888901","quote_policy":"short_quote_link_out"},{"id":"pubmed:38008031","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1002677337564045313:f6a23d83-5dd8-46ee-bcdf-8998e0d35475","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1002677565235056645:31ee80f8-33cf-4753-b605-151358898237","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1178305640277655553:3e53f2fe-418d-4e9e-af28-0978b6588f3e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1228713983525277696:6af3ceba-aab2-42a7-8fe5-1bad7cc3b6a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1228717311923613696:136bb4b4-df4d-48c2-b772-a938e5c95c18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1360661540463022081:75cda085-ad7d-4cfc-b074-ef5f7190cbcc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1385275739432488963:929da53d-8b77-42fc-86dc-9a5cdfb9819e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533166772366475265:28a32d03-5f3c-4dd8-9f71-fc9994b9b468","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533195465277288448:03226f1c-8579-4d0c-8cc9-518dc9a61696","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533203858436112385:d0726572-86ec-4523-8006-2c139372ceb1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1563557274399870978:4eb49e60-4777-4dee-aaa2-d35111a68d64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1589347123870449673:20bb1b16-5ef9-488e-a8fb-f0aa0b96e978","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1628798003757588484:6c5bcf4a-e136-4617-8804-0d87115d8ce8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716446939804213308:cc0e2339-2328-444f-b272-548b73c04d26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1723049481065627826:6efecd96-b415-45d2-9dd8-80fa6f7058eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1723052852837232732:db7cf338-8e96-4695-8b08-3bb07b696999","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1723091324595798233:afbd1ca7-2eef-490c-95e3-f41d4516b5c0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1864716599971729761:054e8a3d-c1a6-4a0f-82cd-7186489fb9a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1990585201844760757:d1148ac7-8dec-4001-b4f5-0687e2335ac1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112368469018866114:836a4f71-3aba-4e24-879f-385c38cf9ee2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1385252642549641220","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FWdcSJAwjhM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:WLUJrIbD0oU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:_nzU5jSXy8Q","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:go-FsfR3wlo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:n5QMqyCseFQ","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":20,"x_video":1,"youtube":5},"by_evidence_role":{"commentary":26},"count":26,"evidence_window":{"end":"2026-10-20","start":"2018-06-01"},"retrieval_snapshot":"2026-11-21T09:43:09.124301Z","timeline":[{"count":2,"week":"2018-W22"},{"count":1,"week":"2019-W39"},{"count":3,"week":"2020-W07"},{"count":1,"week":"2020-W08"},{"count":1,"week":"2020-W11"},{"count":1,"week":"2021-W06"},{"count":1,"week":"2021-W09"},{"count":2,"week":"2021-W16"},{"count":1,"week":"2021-W31"},{"count":3,"week":"2022-W22"},{"count":1,"week":"2022-W34"},{"count":1,"week":"2022-W44"},{"count":1,"week":"2023-W08"},{"count":1,"week":"2023-W43"},{"count":3,"week":"2023-W45"},{"count":1,"week":"2024-W49"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2026-W43"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":15,"registry":0,"regulatory":0,"x_thread":33,"x_video":4,"youtube":35}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Welireg"],"label":"belzutifan","slug":"belzutifan"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Advanced solid tumors","slug":"advanced-solid-tumors"},{"reason":"Unmapped registry condition: Solid Tumor","status":"unmapped"},{"reason":"Unmapped registry condition: Solid Carcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Solid Tumor, Adult","status":"unmapped"},{"reason":"Unmapped registry condition: ccRCC","status":"unmapped"},{"reason":"Unmapped registry condition: RCC, Clear Cell Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: RCC","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Renal cell carcinoma","slug":"renal-cell-carcinoma"},{"reason":"Unmapped registry condition: Clear Cell Renal Cell Carcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Renal Cell Carcinoma, Metastatic","status":"unmapped"},{"reason":"Unmapped registry condition: Renal Cell Carcinoma Recurrent","status":"unmapped"},{"reason":"Unmapped registry condition: Renal Cell Carcinoma, Clear Cell Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Glioblastoma","status":"unmapped"},{"reason":"Unmapped registry condition: Glioblastoma, Adult","status":"unmapped"},{"reason":"Unmapped registry condition: GBM","status":"unmapped"},{"reason":"Unmapped registry condition: Glioblastoma Multiforme","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"LITESPARK-001","aliases":["LITESPARK-001","MK-6482-001","A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)","A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors"],"brief_title":"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Advanced Solid Tumors","Solid Tumor","Solid Carcinoma","Solid Tumor, Adult","ccRCC","RCC, Clear Cell Adenocarcinoma","RCC","Kidney Cancer","Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma, Metastatic","Renal Cell Carcinoma Recurrent","Renal Cell Carcinoma, Clear Cell Adenocarcinoma","Glioblastoma","Glioblastoma, Adult","GBM","Glioblastoma Multiforme"],"display_condition":"advanced solid tumors","display_interventions":[["belzutifan"]],"enrollment":{"count":120,"type":"ACTUAL"},"interventions":[{"name":"Belzutifan","synonyms":["PT2977 Tablets, PT-2977, HIF-2α inhibitor, MK-6482","WELIREG™"],"type":"DRUG"}],"nct_id":"NCT02974738","official_title":"A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2018-01-12","type":"ACTUAL"},"primary_endpoints":[{"description":"21-Day Dose Limiting Toxicity Observation Period per Dose Group","measure":"maximum tolerated dose (MTD)","timeFrame":"3 Weeks"}],"registered_date":{"date":"2016-11-28","type":"ESTIMATED"},"registry_last_updated":"2026-10-26","registry_url":"https://clinicaltrials.gov/study/NCT02974738","short_name":"LITESPARK-001","short_name_basis":"canonical_name","sponsor":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","start_date":{"date":"2016-12-07","type":"ACTUAL"},"study_design":"interventional, non randomized, single group, phase1","study_ids":[{"id":"6482-001","type":"sponsor_study_id"},{"domain":"Pelaton Study ID","id":"PT2977-101","type":"other"},{"domain":"MSD","id":"MK-6482-001","type":"other"}],"study_type":"INTERVENTIONAL"}}}